Description

Pfizer’s competitive quality improvement program funds practice-based efforts to address barriers in the homologous recombination repair mutation (HRRm) testing pathway for metastatic prostate cancer. It seeks multidisciplinary changes to clinical workflows that make testing more efficient, reliable, and consistent while reducing clinicians’ administrative and operational burden, particularly in community and office-based care.

Projects may improve sample adequacy, pilot coordination across the testing pathway, evaluate locally appropriate reflex testing, or use implementation science and existing technology to resolve workflow gaps. Proposals should measure improvements in testing rates, continuity, timeliness, result use, or care coordination, with sustainable approaches that can work in both academic and community settings. The program funds testing processes and care delivery, not clinical research evaluating diagnostic or therapeutic products.